Description
LYT-200 is an investigational medication being studied by PureTech. It is currently in early-phase clinical trials (Phase 1) for various advanced solid tumors, including colorectal cancer. The trials are designed to determine the appropriate dose and assess safety. LYT-200 is being tested both by itself and in combination with other treatments like chemotherapy or tislelizumab (an immunotherapy drug). The trials are looking at patients whose cancer has spread or cannot be removed with surgery. Some trials specifically include patients with certain genetic changes (like EGFR mutations) or protein levels (like PD-L1 expression) on their cancer cells, as these might predict how well the drug works. The goal of these early trials is to find the best way to use LYT-200 and understand its effects before testing it in larger groups of patients.
Mechanism of Action
LYT-200 is being investigated as a potential treatment for advanced solid tumors. The specific way it works (its molecular target or mechanism of action) is still being studied in clinical trials. Researchers are evaluating how LYT-200 affects cancer cells and the body's response to cancer.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.